The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 6, 2010, Pages 713-722

  Zhang, L ^a   Mei, Q ^a   Li, Q S ^a   Hu, Y M ^a   Xu, J M ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

cytochrome P450; genetic polymorphism; Helicobacter pylori; interleukin 1; proton pump inhibitor; triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; OMEPRAZOLE; RABEPRAZOLE;

ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; ERADICATION THERAPY; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMOZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTON PUMPS; YOUNG ADULT;

EID: 78449290703     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01140.x     Document Type: Article

References (54)

1. Egan BJ, Katicic M, O'Connor HJ, O'Morain CA, (2007) Treatment of Helicobacter pylori. Helicobacter, 12, 31-37.
2. Malfertheiner P, Megraud F, O'Morain C, et al. (2007) Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut, 56, 772-781. (Pubitemid 46854190)
3. Megraud F, (2004) H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut, 53, 1374-1384.
4. Suzuki T, Matsuo K, Ito H, et al. (2006) Smoking increases the treatment failure for Helicobacter pylori eradication. American Journal of Medicine, 119, 217-224.
5. Suzuki T, Matsuo K, Sawaki A, et al. (2007) Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiology and Infection, 135, 171-176.
6. Klotz U, (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. International Journal of Clinical Pharmacology and Therapeutics, 44, 297-302.
7. Sugimoto M, Furuta T, Shirai N, et al. (2007) Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter, 12, 317-323.
8. Adachi K, Katsube T, Kawamura A, et al. (2000) CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Alimentary Pharmacology and Therapeutics, 14, 1259-1266.
9. Horai Y, Kimura M, Furuie H, et al. (2001) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Alimentary Pharmacology and Therapeutics, 15, 793-803.
10. Furuta T, Ohashi K, Kosuge K, et al. (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clinical Pharmacology and Therapeutics, 65, 552-561.
11. Horn J, (2004) Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Alimentary Pharmacology and Therapeutics, 20, 11-19.
12. Vergara M, Vallve M, Gisbert JP, Calvet X, (2003) Meta-analysis: comparative efficacy of different proton pump inhibitors in triple therapy for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 18, 647-654. (Pubitemid 37186615)
13. Inaba T, Mizuno M, Kawai K, et al. (2002) Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. Journal of Gastroenterology and Hepatology, 17, 748-753.
14. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M, (2001) Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Digestive and Liver Disease, 33, 671-675.
15. Catalano F, Terminella C, Branciforte G, Bentivegna C, Brogna A, Scalia A, (2002) Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. Digestion, 66, 154-159.
16. Vakil N, Lanza F, Schwartz H, Barth J, (2004) Seven-day therapy for Helicobacter pylori in the United States. Alimentary Pharmacology and Therapeutics, 20, 99-107.
17. Miwa H, Ohkura R, Murai T, et al. (1999) Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Alimentary Pharmacology and Therapeutics, 13, 741-746.
18. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N, (2001) Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis. Digestive Diseases and Sciences, 46, 2445-2450.
19. Furuta T, Shirai N, Takashima M, et al. (2001) Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics, 11, 341-348. (Pubitemid 32537408)
20. Miyoshi M, Mizuno M, Ishiki K, et al. (2001) A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. Journal of Gastroenterology and Hepatology, 16, 723-728.
21. Jung HC, Kim JM, Song IS, Kim CY, (1997) Helicobacter pylori induces an array of pro-inflammatory cytokines in human gastric epithelial cells: quantification of mRNA for interleukin-8, -1 alpha/beta, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and tumour necrosis factor-alpha. Journal of Gastroenterology and Hepatology, 12, 473-480.
22. Robert A, Olafsson AS, Lancaster C, Zhang WR, (1991) Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Science, 48, 123-34.
23. Serrano MT, Lanas AI, Lorente S, Sáinz R, (1997) Cytokine effects on pepsinogen secretion from human peptic cells. Gut, 40, 42-48.
24. Dinarello CA, (1984) Interleukin-1. Reviews of Infectious Diseases, 6, 51-95.
25. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW, (1993) Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Human Genetics, 91, 403-404.
26. Di Giovine FS, Takhsh E, Blakemore AI, Duff GW, (1992) Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Human Molecular Genetics, 1, 450.
27. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J, (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. European Journal of Clinical Investigation, 22, 396-402.
28. Danis VA, Millington M, Hyland VJ, Grennan D, (1995) Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clinical and Experimental Immunology, 99, 303-310.
29. Andus T, Daig R, Vogl D, et al. (1997) Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2. Gut, 41, 651-657.
30. Tountas NA, Casini-Raggi V, Yang H, et al. (1999) Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology, 117, 806-813.
31. El-Omar EM, Carrington M, Chow WH, et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404, 398-402.
32. Hu XP, Xu JM, Hu YM, Mei Q, Xu XH, (2007) Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. Journal of Clinical Pharmacy and Therapeutics, 32, 517-524.
33. Hu YM, Xu JM, Mei Q, Xu XH, Xu SY, (2005) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacologica Sinica, 26, 384-388.
34. De Morais SM, Goldstein JA, Xie HG, et al. (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clinical Pharmacology and Therapeutics, 58, 404-411.
35. Xiao ZS, Goldstein JA, Xie HG, et al. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics, 281, 604-609.
36. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA, (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal Of Biological Chemistry, 269, 15419-15422.
37. Zhang D, Zheng H, Zhou Y, Tang X, Yu B, Li J, (2007) Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer., 7, 45.
38. Bioque G, Crusius JB, Koutroubakis I, Bouma G, Kostense PJ, Meuwissen SG, Peña AS, (1995) Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clinical and Experimental Immunology, 102, 379-83.
39. Williams MP, Pounder RE, (1999) Review article: the pharmacology of rabeprazole. Alimentary Pharmacology and Therapeutics, 13, 3-10.
40. Stedman CA, Barclay ML, (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 14, 963-978.
41. Shimatani T, Moriwaki M, Xu J, Tazuma S, Inoue M, (2006) Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Digestive and Liver Disease, 38, 802-808.
42. Miwa H, Yamada T, Sato K, et al. (2000) Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection. Digestive Diseases and Sciences, 45, 77-82.
43. McColl KE, Kennerley P, (2002) Proton pump inhibitors-differences emerge in hepatic metabolism. Digestive and Liver Disease, 34, 461-467.
44. Robinson M, (2004) Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors-overview and clinical implications. Alimentary Pharmacology and Therapeutics, 20, 1-10.
45. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T, (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics, 5, 181-202.
46. Zhao F, Wang J, Yang Y, et al. (2008) Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter, 13, 532-541.
47. Lim PW, Goh KL, Wong BC, (2005) CYP2C19 genotype and the PPIs focus on rabeprazole. Journal of Gastroenterology and Hepatology, 20 (Suppl.), S22-S28.
48. Kuwayama H, Asaka M, Sugiyama T, et al. (2007) Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Alimentary Pharmacology and Therapeutics, 25, 1105-1113.
49. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH, (2006) The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. American Journal of Gastroenterology, 101, 1467-1475.
50. Furuta T, Ohashi K, Kamata T, et al. (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Annals of Internal Medicine, 129, 1027-1030.
51. Furuta T, Sugimoto M, Shirai N, Ishizaki T, (2007) CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics, 8, 1199-1210.
52. Hartland S, Newton JL, Griffin SM, Donaldson PT, (2004) A functional polymorphism in the interleukin-1 receptor-1 gene is associated with increased risk of Helicobacter pylori infection but not with gastric cancer. Digestive Diseases and Sciences, 49, 1545-1550.
53. Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T, (2006) Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clinical Pharmacology and Therapeutics, 80, 41-50.
54. Take S, Mizuno M, Ishiki K, et al. (2003) Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. American Journal of Gastroenterology, 98, 2403-2408.